50 results about "Atopic dermatitis (eczema)" patented technology

The present invention relates to anti IL13 antibodies that hind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

The present invention relates to compositions comprising a proanthocyanidin, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. The present invention also relates to compositions comprising a proanthocyanidin, glycyrrhetinic acid and telmesteine, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye.

This invention relates to a topical pharmaceutical composition comprising a combination of methotrexate, alpha bisabolol and allantoin; a process for producing the same and the use of the composition in the treatment of plaque psoriasis (psoriasis vulgaris), atopic dermatitis and chronic eczema. The composition of this invention can be used alone or in combination with other topical or systemic therapies. The present invention further discloses a process for producing the pharmaceutical composition.

Provided is a novel JAK3 inhibitor useful as a preventive and / or therapeutic agent for organ transplant rejection, graft versus host disease (GvHD), rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic conjunctivitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia, etc. A pyridine-3-carboxyamide derivative represented by general formula (1) or a salt thereof or a solvate thereof are also provided.

The present invention addresses the problem of providing a coating-forming-type skin composition (coating-type skin protective agent, coating-type skin topical agent, or the like) that does not contain a lower monovalent alcohol such as ethanol and isopropanol, that has excellent quick-drying ability and water resistance, and that is less sticky and provides excellent sensation when being used. The present invention pertains to a coating-forming-type skin composition characterized by containing a specific acrylic polymer, a plasticizing agent, and water, but substantially not containing a lower monovalent alcohol such as ethanol and isopropanol. The composition according to the present invention is extremely useful in the therapy of chronic skin diseases, etc., represented by hand eczema, atopic dermatitis, or the like (i.e., skin diseases with reduced skin barrier function).

This invention provides a pharmaceutical composition for topical application to the skin of a patient in need of, comprising neramexane or a pharmaceutically acceptable salt thereof, and at least one gel forming agent for the treatment or prevention of inflammatory skin diseases such as impetigo contagiosa, acne, rosacea, eczema, atopic dermatitis, contact dermatitis, seborrheic dermatitis, psoriasis, and / or oily skin. The at least one gel forming agent comprises polymers with neutral and / or positively charged polymer backbones.

The present invention provides purified protease inhibitors derived from microorganisms alone or in combination with bacteriocins and / or antibodies. The protease inhibitors may also be expressed by microbiome or probiotic microorganisms alone or in combination with bacteriocins and / or antibodies. The invention also provides methods and compositions for improving the expression of endogenous or heterologous protease inhibitors alone or in combination with bacteriocins and / or antibodies. The invention is useful for treating a variety of inflammatory disorders including acne, psoriasis, eczema, atopic dermatitis and inflammatory bowel disease.

A topical medication including a therapeutically effective amount of an AMPK (adenosine monophosphate-activated protein kinase) agonist for use in the treatment of one or more the human or animal medical conditions. The medical conditions include, but are not limited to: shingles (herpes zoster), post-herpetic neuralgia (PHN), gout, migraine, trigeminal neuralgia, Complex Regional Pain Syndrome (CRPS), diabetic neuropathy, peripheral neuropathy, rheumatoid arthritis, insect-related wheals, urushiol-related rash, psoriasis, herpes simplex, atopic dermatitis (eczema), contact dermatitis, allergic dermatitis, neurotrophic ulcers, first- and second-degree burns (e.g., sunburn and chemical), fibromyalgia, rubeola, and acne. Also disclosed are a method of employing the composition and a wound dressing incorporating a therapeutically effective amount of an AMPK agonist in combination with an antimicrobial agent.

The present invention provides a clobetasol propionate and tretinoin ointment agent. According to the present invention, a phospholipid and a positively charged lipid are mainly adopted to wrap drugs to prepare a lipid complex, wherein the positively charged lipid complex can concurrently wrap two drugs, encapsulation efficiency is high, and leakage is not easily generated; with the lipid complex, drug absorption can be promoted, and drug retention in skin can be increased; the multi-component low co-melting system is adopted to prepare the solid dispersion, such that the composite antioxidant component in the formula is uniformly dispersed in the same system; an oil phase matrix and an emulsifying agent are added so as to further prepare into a cream agent or an ointment agent in one step; and the preparation has characteristics of good emulsifying uniformity and high stability, and can be used for treatment of psoriasis, chronic dermatitis and eczema, skin papule type amyloidopathia, lichen planus, and non-atopic dermatitis.

A carboxylic acid compound represented by formula (I): (meanings of the symbols in the formula are as mentioned in the specification) and a pharmaceutical agent comprising the compound. <>Since the compound represented by formula (I) binds to a DP receptor and shows antagonistic activity for the DP receptor, it is useful for prevention and / or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like. Carboxylic acid compounds represented by the following general formula (I) (wherein each symbol is as defined in the description) and drugs containing these compounds: (I) Because of binding to DP receptor and antagonizing the same, the compounds represented by the general formula (I) are useful in preventing and / or treating allergic diseases (allergic nephritis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, etc.), systemic mast cell disease, systemic mast cell activation failure, anaphylactic shock, respiratory tract contraction, urticaria, eczema, diseases associated with itch (atopic dermatitis, urticaria, etc.), diseases (cataract, retinal detachment, inflammation, infection, sleep disorder, etc.) secondarily caused by behaviors associating itch (scratching, beating.

To provide a novel JAK3 inhibitor that is useful as a preventive and / or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.

This invention relates to a topical pharmaceutical composition comprising a combination of methotrexate, alpha bisabolol and allantoin; a process for producing the same and the use of the composition in the treatment of plaque psoriasis (psoriasis vulgaris), atopic dermatitis and chronic eczema. The composition of this invention can be used alone or in combination with other topical or systemic therapies. The present invention further discloses a process for producing the pharmaceutical composition.

The invention relates to a compound preparation for treating skin inflammation and a preparation method thereof. The raw materials of the preparation are Coptis chinensis, rhubarb rhubarb, rose, and gall, which are extracted by solvent, impurity removal, concentration or drying, and medically acceptable auxiliary materials. Made into ointments, gels, tinctures, varnishes or liniments. The compound preparation has antibacterial, anti-inflammatory and astringent effects, and is used for treating skin inflammations including acute and chronic eczema, atopic dermatitis, contact dermatitis and allergic dermatitis. Pharmacodynamic studies have shown that the compound preparation of the present invention effectively inhibits NO activity, can inhibit the release of NO, can significantly reduce the degree of inflammation of skin lesions, and can increase IL-2, IL-4, The level of IL-18 is reduced, and the level of TNF-α and IL-12 caused by dermatitis and eczema is reduced, and the balance of Th1 cells and Th2 cells is achieved, which plays a therapeutic role.